332 related articles for article (PubMed ID: 28186973)
1. Upregulation of FAM84B during prostate cancer progression.
Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
[TBL] [Abstract][Full Text] [Related]
2. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.
Lin X; Gu Y; Kapoor A; Wei F; Aziz T; Ojo D; Jiang Y; Bonert M; Shayegan B; Yang H; Al-Nedawi K; Major P; Tang D
Neoplasia; 2017 Nov; 19(11):857-867. PubMed ID: 28930697
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.
Gordon JA; Noble JW; Midha A; Derakhshan F; Wang G; Adomat HH; Tomlinson Guns ES; Lin YY; Ren S; Collins CC; Nelson PS; Morrissey C; Wasan KM; Cox ME
Cancer Res; 2019 Jul; 79(13):3320-3331. PubMed ID: 31064850
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer.
Wang Z; Wu D; Ng CF; Teoh JY; Yu S; Wang Y; Chan FL
Endocr Relat Cancer; 2018 Jan; 25(1):35-50. PubMed ID: 29042395
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
[TBL] [Abstract][Full Text] [Related]
7. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis.
Xie Y; Yan J; Cutz JC; Rybak AP; He L; Wei F; Kapoor A; Schmidt VA; Tao L; Tang D
Biochim Biophys Acta; 2012 Jun; 1822(6):875-84. PubMed ID: 22406297
[TBL] [Abstract][Full Text] [Related]
8. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
[TBL] [Abstract][Full Text] [Related]
9. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis.
Yan J; De Melo J; Cutz JC; Aziz T; Tang D
Br J Cancer; 2014 May; 110(10):2593-603. PubMed ID: 24762960
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
12. Direct interaction of β-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer.
Pan KF; Lee WJ; Chou CC; Yang YC; Chang YC; Chien MH; Hsiao M; Hua KT
EMBO J; 2021 Feb; 40(4):e105450. PubMed ID: 33347625
[TBL] [Abstract][Full Text] [Related]
13. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
[TBL] [Abstract][Full Text] [Related]
15. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
16. Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.
Adisetiyo H; Liang M; Liao CP; Jeong JH; Cohen MB; Roy-Burman P; Frenkel B
J Cell Physiol; 2014 Sep; 229(9):1170-6. PubMed ID: 24752784
[TBL] [Abstract][Full Text] [Related]
17. Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.
Yan J; Ojo D; Kapoor A; Lin X; Pinthus JH; Aziz T; Bismar TA; Wei F; Wong N; De Melo J; Cutz JC; Major P; Wood G; Peng H; Tang D
Cancer Res; 2016 Mar; 76(6):1603-14. PubMed ID: 26795349
[TBL] [Abstract][Full Text] [Related]
18. FAM84B promotes prostate tumorigenesis through a network alteration.
Jiang Y; Lin X; Kapoor A; He L; Wei F; Gu Y; Mei W; Zhao K; Yang H; Tang D
Ther Adv Med Oncol; 2019; 11():1758835919846372. PubMed ID: 31205500
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
20. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.
Germann M; Wetterwald A; Guzmán-Ramirez N; van der Pluijm G; Culig Z; Cecchini MG; Williams ED; Thalmann GN
Stem Cells; 2012 Jun; 30(6):1076-86. PubMed ID: 22438320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
